Clinical Core

项目描述/摘要-临床核心 临床中心将作为马约ADRC的协调中心。马约抗抑郁药审查委员会的临床核心 一直是阿尔茨海默病中心在招募和留住参与者方面的领导者。的 马约ADRC已经并将继续专注于阿尔茨海默病谱（AD）的成像，遗传学， 额颞叶变性（FTLD）疾病组的成像和自然病史以及成像， 相关特征（睡眠、帕金森症、幻觉等）和路易体疾病的自然史 (LBD)阿尔茨海默病相关病症（FTLD和LDB统称为阿尔茨海默病相关病症“ADRD”）。中的每 这些病原学实体，马约研究人员持有NIH赠款，部分原因是ADRC利用ADRC 参与者池。在上一个资助周期中，我们大大增加了参与者的数量， 包括非裔美国人，他们接受了淀粉样蛋白PET成像。此外，在上一个赠款周期，我们 在MCR组中也引入了tau PET成像，我们很快将在MCF组中这样做。有很多 我们对AD和ADRD的共同兴趣产生了协同作用，既用于临床表征，也用于 生物标志物评估和基础科学共性。临床核心诊断和评价活动 将在MCR和MCF中进行，并将从评估方案中得出的数据输入到 单一数据库。UDS 3的核心程序是根据NACC准则执行的， 还对我们的方案进行了额外的评估。所有患者和对照组均接受 在2-3天内进行标准化系列访谈、检查和生物标志物研究。所有与会者 由神经心理学家和神经科医生进行检查。我们的具体目标是（1）招募，跟踪和供应给其他 项目，AD谱系障碍患者;（2）招募，跟踪和提供给其他项目的患者， ADRD谱;（3）招募患有上述疾病的非洲裔美国人（与ORE Core合作）;（4） 获取DNA、血液、脑脊液（与Biomarker Core合作）和多模式成像 （与神经影像学核心合作）;以及（5）获得临床核心参与者的尸检 （与神经病理学核心合作）。

PROJECT DESCRIPTION/ABSTRACT – CLINICAL CORE The Clinical Core will serve as the focal point of the Mayo ADRC. The Clinical Core of the Mayo ADRC has been among the leaders among Alzheimer's Disease Centers in recruiting and retaining participants. The Mayo ADRC has focused and will continue to focus on imaging in the Alzheimer spectrum (AD), the genetics, imaging and natural history of Frontotemporal Lobar Degeneration (FTLD) group of disorders and the imaging, associated features (sleep, Parkinsonism, hallucinations, etc) and natural history of Lewy Body disorders (LBD) spectrum (FTLD and LDB collectively the Alzheimer's disease related disorders “ADRD”). For each of these etiologic entities, Mayo investigators hold NIH grants, in part due to the ADRC that utilize the ADRC participant pool. Over the last cycle of funding, we have greatly expanded the number of participants, including African Americans, who have undergone amyloid PET imaging. Moreover in the last grant cycle, we introduced tau PET imaging as well in the MCR group, and we will do so soon in MCF. There are many synergies that arise from our concurrent interest in AD and ADRD both for clinical characterization, but also for biomarker evaluations, and basic science commonalities. The Clinical Core diagnostic and evaluative activities will take place in both MCR and MCF, and the data derived from the evaluation schemes are entered into a single database. The core procedures of the UDS3 are carried out according to NACC guidelines, and additional evaluations specific to our programs are also conducted. All patients and controls undergo a standardized series of interviews, examinations and biomarkers studies over 2-3 days. All participants are seen by a neuropsychologist and neurologist. Our Specific Aims are to (1) Recruit, follow and supply to other projects, patients with AD spectrum disorders; (2) Recruit, follow and supply to other projects patients, in the ADRD spectrum; (3) Recruit African-Americans with above disorders (collaborating with ORE Core); (4) Obtain DNA, blood, cerebrospinal fluid (collaborating with Biomarker Core) and multimodal imaging (Collaborating with Neuroimaging Core) on participants; and (5) Obtain autopsies on Clinical Core participants (collaborating with Neuropathology Core).